JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 2, 2005; DOI: 10.1124/jpet.104.082784


0022-3565/05/3133-1248-1253$20.00
JPET 313:1248-1253, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.082784v1
313/3/1248    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Budzyn, K.
Right arrow Articles by Sobey, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Budzyn, K.
Right arrow Articles by Sobey, C. G.

CARDIOVASCULAR

Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension

Klaudia Budzyn, Philip D. Marley, and Christopher G. Sobey

Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia

Phosphatidylinositol 3-kinase (PI3K) can activate endothelial nitric oxide synthase (eNOS), leading to production of the vasodilator NO. In contrast, vascular smooth muscle (VSM) PI3K may partially mediate vascular contraction, particularly during hypertension. We tested whether endothelial and VSM PI3K may have opposing functional roles in regulating vascular contraction. Secondly, we tested whether the procontractile protein rho-kinase can suppress endothelial PI3K/eNOS activity in intact arteries, thus contributing to vasoconstriction by G protein-coupled receptor (GPCR) agonists. We studied contractile responses to the GPCR agonist phenylephrine, and the receptor-independent vasoconstrictor KCl, in aortic rings from Sprague-Dawley rats. In endothelium-intact rings, the PI3K inhibitor wortmannin (0.1 µM) markedly augmented responses to phenylephrine (P < 0.05) by ~50% but not to KCl. However, in endothelium-denuded or NG-nitro-L-arginine methyl ester (L-NAME) (100 µM)-treated rings, wortmannin reduced responses to phenylephrine and KCl (P < 0.05). Furthermore, the rhokinase inhibitor Y-27632 (R-[+]-trans-N-[4-pyridyl]-4-[1-aminoethyl]-cycloheaxanecarboxamide; 1 µM) abolished responses to phenylephrine, and this effect was partially reversed by wortmannin or L-NAME. The ability of wortmannin to oppose the effect of rho-kinase inhibition on contractions to phenylephrine was L-NAME-sensitive. In aortas from angiotensin II-induced hypertensive rats, relaxation to acetylcholine (10 µM) was impaired (P < 0.05), and vasoconstriction by phenylephrine was markedly enhanced and not further augmented by wortmannin. These data suggest that endothelial PI3K-induced NO production can modulate GPCR agonist-induced vascular contraction and that this effect is impaired in hypertension in association with endothelial dysfunction. In addition, endothelial rho-kinase may act to suppress PI3K activity and, hence, attenuate NO-mediated relaxation and augment GPCR-dependent contraction.


Received December 23, 2004; accepted February 24, 2005.

Address correspondence to: Dr. Christopher G. Sobey, Department of Pharmacology, University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia. E-mail: cgsobey{at}unimelb.edu.au




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. S. Thompson-Torgerson, L. A. Holowatz, N. A. Flavahan, and W. L. Kenney
Cold-induced cutaneous vasoconstriction is mediated by Rho kinase in vivo in human skin
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1700 - H1705.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
T. Nagaoka, T. W. Hein, A. Yoshida, and L. Kuo
Simvastatin Elicits Dilation of Isolated Porcine Retinal Arterioles: Role of Nitric Oxide and Mevalonate-Rho Kinase Pathways
Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 825 - 832.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
R. Gros, Q. Ding, S. Armstrong, C. O'Neil, J. G. Pickering, and R. D. Feldman
Rapid effects of aldosterone on clonal human vascular smooth muscle cells
Am J Physiol Cell Physiol, February 1, 2007; 292(2): C788 - C794.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Kobayashi, Y. Hayashi, K. Taguchi, T. Matsumoto, and K. Kamata
ANG II enhances contractile responses via PI3-kinase p110{delta} pathway in aortas from diabetic rats with systemic hyperinsulinemia
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H846 - H853.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Chrissobolis and C. G. Sobey
Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease
Stroke, August 1, 2006; 37(8): 2174 - 2180.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Budzyn, M. Paull, P. D. Marley, and C. G. Sobey
Segmental Differences in the Roles of Rho-Kinase and Protein Kinase C in Mediating Vasoconstriction
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 791 - 796.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.